Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANL vs DAWN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DAWN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

DAWN Overall Winner 6-Pillar Tally: ANL 1 – 4 DAWN (1 Tie) Matrix Metrics: ANL 2 – 6 DAWN

As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANL carries a Unified Composite Score of 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin), whereas DAWN carries 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin).

  • Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ANL 48.3/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANL vs DAWN
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $10.30 · SMA50: $12.92
DAWN NASDAQ Head-to-Head Winner
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
TTM Revenue $158M
Forward P/E N/M
Beta / 30D Vol 0.03β · 2% Vol
Unified Composite Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (28.9% over 20 days), RSI 80
RSI-14: 80.5 · SMA20: $21.45 · SMA50: $18.01

6-Pillar Scorecard Institutional Category Breakdown (ANL 1 – 4 DAWN)

Columns: Metric · ANL · DAWN
1. Valuation Multiples DAWN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 37.5x 14.0x
2. Growth & Scale DAWN
Revenue Growth (YoY) +178.1% +83.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $18M $158M
Market Cap $677.5M $2.2B
3. Profitability & Quality DAWN
Gross Margin 100.0% 89.1%
Operating Margin -123.5% -51.1%
Net Profit Margin -124.8% -67.8%
Return on Equity (ROE) -20.2% -22.7%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$22M EBITDA -$124M EBITDA
Cash Flow Margin -119.9% EBITDA Mgn -78.6% EBITDA Mgn
Net Cash / Leverage $3.34 Book/Sh · -20.2% ROE $4.28 Book/Sh · -22.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DAWN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.6% (<1st %ile)
Put/Call OI Skew N/A 0.45x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANL (2) vs DAWN (6)
Institutional Metric ANL DAWN Criterion Row Edge
Market Capitalization
Scale
$677.5M $2.2B Larger Scale DAWN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+178.1% +83.9% Higher Growth ANL
Operating Margin (TTM)
Profitability
-123.5% -51.1% Higher Margin DAWN
Net Profit Margin
Profitability
-124.8% -67.8% Higher Margin DAWN
Return on Equity (ROE)
Capital Efficiency
-20.2% -22.7% Higher ROE ANL
52-Week Range Position
Momentum
56% ($1–$17) 100% ($6–$22) Stronger Trend DAWN
Beta / 30D Volatility
Risk Regime
2.61β · 79% Vol 0.03β · 2% Vol Lower Realized Risk DAWN
Unified Institutional Score
Composite Signal
48.3 / 100 (HOLD) 58.3 / 100 (HOLD) Higher Composite DAWN
Trailing 12M Revenue (USD)
Operating Scale
$18M $158M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 89.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 37.5x EV/Rev N/M PEG · 14.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) -$124M EBITDA ($4.28 Book/Sh · -22.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANL +131.62 pp
ANL: +132.42% · DAWN: +0.8%
3M Horizon ANL +693.51 pp
ANL: +771.89% · DAWN: +78.38%
6M Horizon ANL +824.93 pp
ANL: +968.21% · DAWN: +143.28%
1Y Horizon ANL +824.93 pp
ANL: +968.21% · DAWN: +143.28%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs DAWN. Trailing 12-month operating profitability (ANL -123.5% vs DAWN -51.1%) and valuation multiples (ANL N/M vs DAWN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M
DAWN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$158M
Gross Margin89.1%
Op. Margin-51.1%
ROE / Fwd P/E-22.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DAWN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact DAWN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DAWN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANL vs DAWN Key Questions & Quantitative Answers

As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANL carries a Unified Composite Score of 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin), whereas DAWN carries 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin). Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ANL 48.3/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DAWN leads the Growth & Scale pillar: ANL posts +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin), compared with DAWN at +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin). On trailing 12-month operating scale, ANL generates $18M in USD-normalized revenue versus $158M for DAWN. In operating R&D and SG&A reinvestment, ANL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DAWN.

DAWN screens cheaper on headline valuation multiples. ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin), whereas DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANL (-20.2% ROE) versus DAWN (-22.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk). By comparison, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.